Research Programs

Chimerix is in the process of screening the 12,000 compound chemical library acquired from the University  of Michigan against all antiviral indications with particular focus on HCV, RSV, HIV and influenza.

Additionally Chimerix continues to conjugate key antiviral development candidates and marketed antivirals that could potentially benefit from our technology.